The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Reads0
Chats0
TLDR
A paradigm shift in the treatment of selected B-cell malignancies is anticipated, moving from targeting primarily the malignant cells toward combining cytotoxic drugs with agents that interfere with the microenvironment's proactive role.About:
This article is published in Blood.The article was published on 2009-10-15 and is currently open access. It has received 543 citations till now.read more
Citations
More filters
Journal ArticleDOI
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu,Patricia Pérez-Galán,Delong Liu,Angelique Biancotto,Stefania Pittaluga,Berengere Vire,Federica Gibellini,Ndegwa Njuguna,Elinor Lee,Lawrence S. Stennett,Nalini Raghavachari,Poching Liu,J. Philip McCoy,Mark Raffeld,Maryalice Stetler-Stevenson,Constance M. Yuan,Richard M. Sherry,Diane C. Arthur,Irina Maric,Therese White,Gerald E. Marti,Peter J. Munson,Wyndham H. Wilson,Adrian Wiestner +23 more
TL;DR: The disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL are identified.
Journal ArticleDOI
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
TL;DR: The results of the reported clinical trials are reviewed and the progress and key emerging factors that may play a role in effecting tumor responses are discussed, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies.
Journal ArticleDOI
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader,Shih Shih Chen,Joseph J. Buggy,Kumudha Balakrishnan,Varsha Gandhi,William G. Wierda,Michael J. Keating,Susan O'Brien,Nicholas Chiorazzi,Jan A. Burger +9 more
TL;DR: It is demonstrated that PCI-32765 effectively inhibits CLL cell migration and survival, possibly explaining some of the characteristic clinical activity of this new targeted agent.
Journal ArticleDOI
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel,Sarah A. Meadows,Mariela Sivina,William G. Wierda,Hagop M. Kantarjian,Michael J. Keating,Neill A. Giese,Susan O'Brien,Albert S. Yu,Langdon L. Miller,Brian J. Lannutti,Jan A. Burger +11 more
TL;DR: CAL-101 displays a dual mechanism of action, directly decreasing cell survival while reducing interactions that retain CLL cells in protective tissue microenvironments, and a roadmap for future therapeutic development.
Journal ArticleDOI
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij,Annemieke Kuil,Christian R. Geest,Eric Eldering,Betty Y. Chang,Joseph J. Buggy,Steven T. Pals,Marcel Spaargaren +7 more
TL;DR: The data indicate that inhibition of BTK by PCI-32765 overcomes BCR- and chemokine-controlled integrin-mediated retention and homing of malignant B cells in their growth- and survival-supporting lymph node and bone marrow microenvironment, which results in clinically evident CLL regression.
References
More filters
Journal ArticleDOI
Differential use of very late antigen-4 and -5 integrins by hematopoietic precursors and myeloma cells to adhere to transforming growth factor-beta1-treated bone marrow stroma.
TL;DR: Results indicate that regulation of fibronectin expression on BM stromal cells by TGF-β1 results in a modulation of the pattern of integrins used by the precursor and myeloma cells to adhere to BM stroma, which could have important consequences on the proliferation and differentiation of hematopoietic precursor cells as well as on the localization and growth of myel cancer cells.
Journal ArticleDOI
Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)
Jonathan W. Friedberg,Jeff P. Sharman,Julia Schaefer-Cutillo,Patrick B. Johnston,Sven de Vos,Ann S. LaCasce,John P. Leonard,Larry D. Cripe,Rajni Sinha,Stephanie A. Gregory,John Sweetenham,Julie M. Vose,Ann M. Lowe,Ronald Levy,Margaret A. Shipp +14 more
TL;DR: It is concluded that disrupting BCR-induced signaling by inhibiting SYK kinase represents a safe and well-tolerated novel therapeutic approach to NHL.
Journal ArticleDOI
Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny
Brian J. Taylor,Jitra Kriangkum,Julie A. Pittman,Michael J. Mant,Tony Reiman,Andrew Belch,Linda M. Pilarski +6 more
TL;DR: The presence of a single, unchanging clonotypic switch junction suggests that cIgM cells are not MM-PC progenitors; rather, postswitch PCs arise from a single cIGM cell, and MM- PCs reside in the postswitch population.
Journal ArticleDOI
Accurate identification of paraprotein antigen targets by epitope reconstruction.
TL;DR: E-MAP represents a new investigative tool for analyzing the role of chronic antigenic stimulation in B-lymphoproliferative disorders and provides enough epitope sequence data so as to enable successful protein database searches.
Journal ArticleDOI
Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.
Geoffrey L. Uy,Michael P. Rettig,Kyle McFarland,Lindsay Hladnik,Shashikant Kulkarni,Camille N. Abboud,Amanda F. Cashen,Keith Stockerl-Goldstein,Ravi Vij,Peter Westervelt,John F. DiPersio +10 more
TL;DR: It is found that plerixafor can modestly mobilize leukemic cells into the peripheral circulation at a peak of 6–8 hours after administration, and FISH studies performed from informative samples demonstrates that this mobilization occurs equally in both non-leukemic andLeukemic populations.
Related Papers (5)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu,Patricia Pérez-Galán,Delong Liu,Angelique Biancotto,Stefania Pittaluga,Berengere Vire,Federica Gibellini,Ndegwa Njuguna,Elinor Lee,Lawrence S. Stennett,Nalini Raghavachari,Poching Liu,J. Philip McCoy,Mark Raffeld,Maryalice Stetler-Stevenson,Constance M. Yuan,Richard M. Sherry,Diane C. Arthur,Irina Maric,Therese White,Gerald E. Marti,Peter J. Munson,Wyndham H. Wilson,Adrian Wiestner +23 more
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Tarun Wasil,Franco Fais,Franco Fais,Franco Fais,Fabio Ghiotto,Fabio Ghiotto,Fabio Ghiotto,Angelo Valetto,Angelo Valetto,Angelo Valetto,Steven L. Allen,Steven L. Allen,Steven L. Allen,Aby Buchbinder,Aby Buchbinder,Aby Buchbinder,Daniel R. Budman,Daniel R. Budman,Daniel R. Budman,Klaus Dittmar,Klaus Dittmar,Klaus Dittmar,Jonathan E. Kolitz,Jonathan E. Kolitz,Jonathan E. Kolitz,Stuart M. Lichtman,Stuart M. Lichtman,Stuart M. Lichtman,Philip Schulman,Philip Schulman,Philip Schulman,Vincent Vinciguerra,Vincent Vinciguerra,Vincent Vinciguerra,Kanti R. Rai,Kanti R. Rai,Kanti R. Rai,Manlio Ferrarini,Manlio Ferrarini,Manlio Ferrarini,Nicholas Chiorazzi,Nicholas Chiorazzi,Nicholas Chiorazzi +45 more